Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Life Tables01:22

Life Tables

574
A life table is a statistical tool that summarizes the mortality and survival patterns of a population, providing detailed insights into the likelihood of survival or death across different age intervals within a cohort. By organizing data on survival probabilities and mortality rates, life tables offer a clear snapshot of population dynamics over time. They are extensively used in demography, public health, actuarial science, and ecology to analyze life expectancy, design health interventions,...
574
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

663
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
663
Hazard Rate01:11

Hazard Rate

465
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
465
Actuarial Approach01:20

Actuarial Approach

339
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
339
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

894
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
894

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Inequality-Adjusted Incremental Cost-Effectiveness Ratio.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

A Method for Comparing Health Inequality Impact Magnitudes, with an Illustration for Hypothetical Treatments of 1336 Diseases.

PharmacoEconomics·2026
Same author

Priority setting for environmentally sustainable health care: emerging approaches to fair resource allocation.

The Lancet. Planetary health·2025
Same author

From sex differences to sex inequalities in life expectancy: A cross-country observational benchmarking analysis.

PLoS medicine·2025
Same author

Parsing Risk: What the GBD Models Reveal-and What They Don't.

Journal of the American College of Cardiology·2025
Same author

Salud publica de Mexico·2025

Related Experiment Video

Updated: Feb 28, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss.

Ulrikke J V Hernæs1, Kjell A Johansson2, Trygve Ottersen2

  • 1Department of Research and Development, Haukeland University Hospital, Bergen, Norway. Ulrikke.hernaes@gmail.com.

Pharmacoeconomics
|June 19, 2017
PubMed
Summary

Integrating lifetime health loss into cost-effectiveness analyses (CEAs) is feasible. This approach impacts the cost-effectiveness of interventions, influencing reimbursement decisions by considering the needs of the worse off.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.1K

Related Experiment Videos

Last Updated: Feb 28, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.1K

Area of Science:

  • Health Economics
  • Health Technology Assessment
  • Public Health Policy

Background:

  • Integrating concerns for the worse off with cost-effectiveness is crucial for healthcare priority setting.
  • Norway proposed a framework using lifetime loss of quality-adjusted life-years (QALYs) to define the worse off.
  • Methods for calculating health losses and integrating them into cost-effectiveness analyses (CEAs) are not well-established.

Purpose of the Study:

  • To demonstrate how to calculate lifetime health losses.
  • To integrate these health losses into CEAs using a proposed framework.
  • To assess the impact of this integration on incremental cost-effectiveness ratios (ICERs).

Main Methods:

  • Applied a proposed priority-setting framework to 15 drug economic evaluations.
  • Calculated lifetime health loss for target groups using available data.
  • Used a marginal weighting function to adjust standard ICERs and compared them to a US$35,000/QALY threshold.

Main Results:

  • Lifetime health loss calculation and integration into CEAs are feasible using available data and a marginal weighting function.
  • Integration of health loss significantly altered standard ICERs.
  • The number of cost-effective interventions increased from three to eight after integration.

Conclusions:

  • Calculating and integrating lifetime health loss into CEAs is practical and can impact intervention reimbursement and ranking.
  • Guidelines for economic evaluations should mandate adjustment for distributional concerns and reporting of health loss data.
  • Developing generic databases for health loss data would support regular integration.